Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Anton Porsteinsson MD

Anton P. Porsteinsson MD

William B. and Sheila Konar Professor of Psychiatry, Neurology, Neuroscience, and Medicine; Director, Alzheimer's Disease Care, Research and Education Program (AD-CARE), University of Rochester School of Medicine and Dentistry, Rochester, New York

Anton P. Porsteinsson, MD, is Director of the University of Rochester Alzheimer’s Disease Care, Research and Education Program (AD-CARE). He is the William B. and Sheila Konar Professor of Psychiatry, Neurology, Neuroscience, and Medicine at the University of Rochester School of Medicine and Dentistry.

Dr. Porsteinsson has devoted his career to the care and study of individuals with memory disorders. He has research interests in biomarkers, imaging, and novel agents in the treatment of Alzheimer’s disease and other dementias, both in terms of cognitive loss and behavioral disturbances. He is a leading investigator for several prominent national and international Alzheimer’s disease prevention and treatment trials.

Dr. Porsteinsson is the author and collaborator of hundreds of research publications and serves as site principal investigator for multiple research grants from the National Institutes of Health and other leading funders.

Disclosures

Dr. Porsteinsson reports personal fees from Acadia Pharmaceuticals, Athira, Biogen, Cognitive Research Corp, Eisai, Functional Neuromodulation, IQVIA, Lundbeck, Medscape, Novartis, ONO Pharmaceuticals, and Xenon; grants to his institution from Alector, Athira, Biogen, Cassava, Eisai, Eli Lilly, Genentech/Roche, Vaccinex, NIA, NIMH, and DOD.